November 18th, 20262027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSDLearn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more. Read more
November 17th, 2026Ketamine for Treatment-Resistant Depression: Practical Clinical ConsiderationsClinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions. Read more
November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 16th, 2026Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive DisorderHLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.Read more
November 12th, 2026Digital Gradebook Engagement Scores May Flag Adolescents at Risk for Substance UseTeacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.Read more
November 12th, 2026FDA Shelves Fast-Track Drug Review InitiativeThe FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration. Read more
November 11th, 2026 A Veterans Day Salute: Lessons From 1918 and 2026 for PsychiatristsPsychiatric Times honors those who served with reflections from a World War I diary and new studies on veteran PTSD and suicide risk.Read more
November 9th, 2026NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant DepressionCompass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.Read more